Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34973214

about

Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort Circulating tumor cells: approaches to isolation and characterization Evaluation and consequences of heterogeneity in the circulating tumor cell compartment When Prostate Cancer Circulates in the Bloodstream PSA and beyond: alternative prostate cancer biomarkers Single-cell analyses of circulating tumor cells Notes for developing a molecular test for the full characterization of circulating tumor cells Androgen receptor footprint on the way to prostate cancer progression The mutational landscape of prostate cancer Circulating tumors cells as biomarkers: progress toward biomarker qualification Detection of circulating tumor cells Targeting the androgen receptor in prostate and breast cancer: several new agents in development The promise of circulating tumor cell analysis in cancer management A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back Emerging data on androgen receptor splice variants in prostate cancer Using circulating tumor cells to inform on prostate cancer biology and clinical utility Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer Molecular biomarker analyses using circulating tumor cells Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Circulating Tumor Cell Isolation and Analysis.AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies.ERG induces taxane resistance in castration-resistant prostate cancer Prostate cancer invasion and metastasis: insights from mining genomic data.Molecular sampling of prostate cancer: a dilemma for predicting disease progression.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Highly-sensitive capture of circulating tumor cells using micro-ellipse filters The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.Antibody-based detection of ERG rearrangement-positive prostate cancer A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer Construction of repeat-free fluorescence in situ hybridization probes.

P2860

Q24597444-175F07F0-FE18-4AAE-96D3-7BCB5C715F38 Q24603649-1C428E73-8D17-40F2-A9CC-D1929FAD821A Q24606772-50433E15-70A9-46C9-9C0D-E0CB2BE51416 Q24631347-298E6AB4-9EC6-422E-9EF3-074C38427741 Q26765357-32DF4A55-B20E-4294-9817-39E238D3E61D Q26768470-E0520733-03FB-448D-A1FC-D7ADE4E15C64 Q26770646-E2F7CC26-BDC1-4CD5-A6FB-8ECE6018FD99 Q26778816-3B83A8F2-F875-494B-AE48-993D114B9DE3 Q26778913-06F012DC-D2EF-4991-B2B0-BE21B8443A0A Q26825402-DDEC81AE-A8EE-4B91-BE88-14291A807335 Q26851631-E6784BA3-D90D-4DF1-A5D1-DA43F5F4E1B7 Q26852579-DEA17129-E910-4AFB-9D00-BE09D931B917 Q26859334-B3AE7C2D-9F61-4A98-8FA1-63AC0ADFA32B Q27009424-D4E84519-4D58-4681-95DC-A9DFDD422A83 Q27022113-F6F2EF35-F27C-4D1D-9730-BBDE58E061A2 Q27022638-2837E08A-1378-4467-8455-0B22EAA63EE7 Q27024191-12DA6FDE-EE26-4240-AAFE-9135A2B4A884 Q28070333-A9174268-FA00-466C-A907-6F8E190CF69A Q28077830-B1D277FE-B54D-4601-990B-8FF26CE69B14 Q28083261-D68A4F31-36AE-4FD9-B23C-1F6721980F10 Q28239638-1353B487-9CED-42F4-A40B-28ECA3C068A5 Q28480861-0CA1DE8E-0601-45ED-B3C4-2579040B3B31 Q28749394-74922E06-CE49-4EFB-BA9D-3B30092861EA Q30354652-C556D630-931C-4F2E-ACEF-B7238CC6FA65 Q30358229-31C80A43-FFB4-41AE-814F-3EA9CC7B39BC Q30513836-9BB02C42-5BBF-45D0-AD6F-A676A8615201 Q30581258-3C12E8F3-ECAD-4B9E-9E05-F0909C776D4A Q30602046-0E6BF428-97DE-4DDF-9322-0826F1D6D359 Q30656758-B0630D67-310C-444A-8AB2-B216E31839AE Q33541296-915152F8-1112-4A7A-B1B0-4926DCF2377C Q33621403-2FE72EC3-00B7-4B76-AF81-013C0EAA6FED Q33670178-5259AD42-5311-42AA-8AFB-495B10DBD91B Q33702987-3B0D594A-A013-42CE-837E-939D9448C93D Q33754817-735250DC-61CD-4C79-8A34-9B6C2E798AF6 Q33770374-61C57909-955A-4A6F-9694-0AFE034A5C93 Q33952306-7E25B68A-E0D3-4180-8815-67617E3DF904 Q34009867-68704018-76DA-46C4-9796-705E837E834D Q34036427-9503C139-8918-4F9A-B8AD-C986BE3B9FE5 Q34050388-F6E952AD-028B-4F51-B6A5-DD008709F89E Q34085195-F8C2F8C9-C6B5-4054-BBB7-0EB8D33A656C

P2860

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34973214

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@ast

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@en

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@nl

type

label

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@ast

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@en

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@nl

prefLabel

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@ast

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@en

Characterization of ERG, AR an ...... ion-resistant prostate cancer.

@nl

P1433

Q34973214-113F2743-D603-412D-8A90-D27B483A912A

P1476

Q34973214-5F6D409B-1060-4A0E-AB44-1E12E512B98E

P2093

Q34973214-01B974F1-9641-43A6-A05E-DEF259713B1D

Q34973214-0C71FAA2-F9BD-4BD7-8949-F9D0AE0EC86A

Q34973214-1EA9D8A6-22B1-426A-A884-31BDB3E9C1AE

Q34973214-495D28D1-CC50-407D-942B-994250055EA3

Q34973214-5071A5FA-DFAB-465C-8331-DFA45A8C7999

Q34973214-522C0CB9-8CA7-43FB-B9E9-C9374E559B49

Q34973214-6C53BCD8-0399-4F16-9A82-6CA8AFA01ECD

Q34973214-7AC91939-E98D-480D-8586-8E6EF1F9BF55

Q34973214-7CB95A02-8108-43E5-967B-40DF23DCC151

Q34973214-81FA1520-6586-4F58-9F43-0878CB3AB324

P304

Q34973214-A29B83F8-1AAF-4043-8BC9-5D5B0BF57559

P31

Q34973214-6C3EE9AB-3BD6-489A-AE96-F86B0FF8E7F2

P356

Q34973214-349A3F73-7AD3-450F-94C5-2ECE3E7FB89F

P407

Q34973214-1821D315-B116-420E-AA37-F4324831DF6D

P433

Q34973214-75011756-703E-4210-90EE-1B4A805397AF

P478

Q34973214-CECBFC72-6381-4BCD-9C48-CDDCFFF5A8B8

P50

Q34973214-8042B965-2035-423E-A97C-AAA7466F8D60

Q34973214-95F4641D-A6BB-421E-8CF1-BE93E19C8228

P577

Q34973214-DE7BF491-7C8C-42C7-8567-46978AB04973

P5875

Q34973214-9CAFA116-0172-4808-A5E6-5BE1364E66FD

P698

Q34973214-44FAE34A-88D4-4D2D-BE50-58858F9CD2B6

P921

Q34973214-D186E4B3-8F76-4E60-8971-D83BDD9F7F1B

P356

0008-5472.CAN-08-3667

P1433

Cancer Research

P1476

Characterization of ERG, AR an ...... tion-resistant prostate cancer

@en

P2093

Alison H M Reid

http://www.w3.org/2001/XMLSchema#string

Arturo Molina

http://www.w3.org/2001/XMLSchema#string

Charles Jameson

http://www.w3.org/2001/XMLSchema#string

Christopher Parker

http://www.w3.org/2001/XMLSchema#string

Colin S Cooper

http://www.w3.org/2001/XMLSchema#string

Craig P Carden

http://www.w3.org/2001/XMLSchema#string

David Dearnaley

http://www.w3.org/2001/XMLSchema#string

David Olmos

http://www.w3.org/2001/XMLSchema#string

Elaine Vickers

http://www.w3.org/2001/XMLSchema#string

Emilda Thompson

http://www.w3.org/2001/XMLSchema#string

P304

2912-2918

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-3667

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24250963

http://www.w3.org/2001/XMLSchema#string

P698

19339269

http://www.w3.org/2001/XMLSchema#string

P921